Glenmark Pharmaceuticals Limited — Q1 FY26
Glenmark's Q1 FY26 consolidated revenue was INR 32,644 million, up 0.6% YoY, with India formulation growing 3.7% and North America up 8.9% QoQ to $91M.
neutral
medium
✓ Verified against BSE filing
Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.
Q4 FY25
Generic Flovent 44 mcg approval by end of Q2 FY26
Expects approval for generic Flovent 44 mcg strength by end of Q2 FY2026, with launch thereafter.
Delivered
Current-quarter results and commentary indicate the prior promise was delivered or materially on track.
heuristic_v1